Overview Dividends

(SRPT) Sarepta Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8036071004

RNA Therapeutics, Duchenne Muscular Dystrophy, Gene Therapy, Rare Diseases

SRPT EPS (Earnings per Share)

EPS Growth (3Y CAGR): 8.07%
EPS Trend (3Y Correlation): 45.0%

SRPT Revenue

Revenue Growth (3Y CAGR): 17.15%
Revenue Trend (3Y Correlation): 82.4%

Risk via 10d forecast
Volatility	132%
Value at Risk 5%th	131%

Reward
Sharpe Ratio	-1.25
Alpha Jensen	-95.37

Character
Hurst Exponent	0.450
Beta	0.522

Drawdowns 3y
Max DD	92.72%
Mean DD	34.83%

Description: SRPT Sarepta Therapeutics November 13, 2025

Sarepta Therapeutics (NASDAQ:SRPT) is a commercial-stage biopharma that specializes in RNA-targeted and gene-therapy approaches for ultra-rare neuromuscular disorders, principally Duchenne muscular dystrophy (DMD).

Its approved portfolio includes EXONDYS 51, VYONDYS 53, and AMONDYS 45-exon-skipping antisense oligonucleotides that restore dystrophin production in mutation-specific DMD sub-populations-and ELEVIDYS, an AAV-based gene therapy for ambulatory pediatric DMD patients.

The pipeline extends beyond DMD with SRP-9003, a gene-therapy candidate for limb-girdle muscular dystrophy, and a suite of collaborative programs with partners such as Roche, Arrowhead, Dyno Therapeutics, and academic institutions.

Key recent metrics (Q4 2023) show total revenue of $258 million, driven largely by EXONDYS 51 sales, a net loss of $115 million, and cash & cash equivalents of $1.2 billion, giving the company roughly 18 months of runway at current burn rates.

Sector-wide forces that materially affect Sarepta’s outlook include escalating pricing power for one-time gene therapies (average US list price > $2 billion), expanding payer frameworks for rare-disease treatments, and the FDA’s accelerated approval pathways that can shorten time-to-market for novel exon-skipping agents.

For a deeper, data-driven valuation of SRPT’s risk-adjusted upside, you may find the analytical tools on ValueRay worth exploring.

SRPT Stock Overview

Market Cap in USD	1,847m
Sub-Industry	Biotechnology
IPO / Inception	1997-06-03
Return 12m vs S&P 500	-86.4%
Analyst Rating	4.38 of 5

SRPT Dividends

Currently no dividends paid

SRPT Growth Ratios

CAGR	-45.49%
CAGR/Max DD Calmar Ratio	-0.49
CAGR/Mean DD Pain Ratio	-1.31
Current Volume	4050.2k
Average Volume	4050.2k

Piotroski VR‑10 (Strict, 0-10) 2.0

Net Income (-271.5m TTM) > 0 and > 6% of Revenue (6% = 144.8m TTM)

FCFTA -0.10 (>2.0%) and ΔFCFTA 3.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 74.61% (prev 121.1%; Δ -46.45pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.07 (>3.0%) and CFO -230.1m > Net Income -271.5m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 2.95 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (100.2m) change vs 12m ago -0.21% (target <= -2.0% for YES)

Gross Margin 75.75% (prev 85.92%; Δ -10.17pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 68.06% (prev 45.57%; Δ 22.49pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -9.94 (EBITDA TTM -194.5m / Interest Expense TTM 23.9m) >= 6 (WARN >= 3)

Altman Z'' -3.64

(A) 0.52 = (Total Current Assets 2.72b - Total Current Liabilities 921.4m) / Total Assets 3.49b

(B) -1.33 = Retained Earnings (Balance) -4.64b / Total Assets 3.49b

warn (B) unusual magnitude: -1.33 — check mapping/units

(D) -2.14 = Book Value of Equity -4.64b / Total Liabilities 2.17b

Total Rating: -3.64 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 29.65

1. Piotroski 2.0pt = -3.0

2. FCF Yield -15.22% = -5.0

3. FCF Margin -14.23% = -5.34

4. Debt/Equity 0.95 = 2.06

5. Debt/Ebitda -3.33 = -2.50

6. ROIC - WACC (= -13.91)% = -12.50

7. RoE -20.31% = -2.50

8. Rev. Trend 82.36% = 6.18

9. EPS Trend 44.98% = 2.25

What is the price of SRPT shares?

As of November 13, 2025, the stock is trading at USD 18.00 with a total of 4,050,171 shares traded.
Over the past week, the price has changed by -3.59%, over one month by -18.03%, over three months by -4.26% and over the past year by -84.25%.

Is Sarepta Therapeutics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Sarepta Therapeutics (NASDAQ:SRPT) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 29.65 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SRPT is around 17.15 USD . This means that SRPT is currently overvalued and has a potential downside of -4.72%.

Is SRPT a buy, sell or hold?

Sarepta Therapeutics has received a consensus analysts rating of 4.38. Therefore, it is recommended to buy SRPT.

Strong Buy: 14
Buy: 8
Hold: 4
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the SRPT price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	21.4	18.9%
Analysts Target Price	21.4	18.9%
ValueRay Target Price	18.5	2.9%

SRPT Fundamental Data Overview November 10, 2025

Market Cap USD = 1.85b (1.85b USD * 1.0 USD.USD)
P/E Forward = 8.6655
P/S = 0.7654
P/B = 1.7235
P/EG = 159.25
Beta = 0.522
Revenue TTM = 2.41b USD
EBIT TTM = -238.0m USD
EBITDA TTM = -194.5m USD
Long Term Debt = 1.14b USD (from longTermDebt, last fiscal year)
Short Term Debt = 10.2m USD (from shortTermDebt, last quarter)
Debt = 1.26b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 647.3m USD (from netDebt column, last quarter)
Enterprise Value = 2.26b USD (1.85b + Debt 1.26b - CCE 851.0m)
Interest Coverage Ratio = -9.94 (Ebit TTM -238.0m / Interest Expense TTM 23.9m)
FCF Yield = -15.22% (FCF TTM -343.6m / Enterprise Value 2.26b)
FCF Margin = -14.23% (FCF TTM -343.6m / Revenue TTM 2.41b)
Net Margin = -11.25% (Net Income TTM -271.5m / Revenue TTM 2.41b)
Gross Margin = 75.75% ((Revenue TTM 2.41b - Cost of Revenue TTM 585.4m) / Revenue TTM)
Gross Margin QoQ = 59.19% (prev 75.04%)
Tobins Q-Ratio = 0.65 (Enterprise Value 2.26b / Total Assets 3.49b)
Interest Expense / Debt = 0.77% (Interest Expense 9.73m / Debt 1.26b)
Taxrate = 7.27% (-14.1m / -194.0m)
NOPAT = -220.7m (EBIT -238.0m * (1 - 7.27%)) [loss with tax shield]
Current Ratio = 2.95 (Total Current Assets 2.72b / Total Current Liabilities 921.4m)
Debt / Equity = 0.95 (Debt 1.26b / totalStockholderEquity, last quarter 1.32b)
Debt / EBITDA = -3.33 (negative EBITDA) (Net Debt 647.3m / EBITDA -194.5m)
Debt / FCF = -1.88 (negative FCF - burning cash) (Net Debt 647.3m / FCF TTM -343.6m)
Total Stockholder Equity = 1.34b (last 4 quarters mean from totalStockholderEquity)
RoA = -7.77% (Net Income -271.5m / Total Assets 3.49b)
RoE = -20.31% (Net Income TTM -271.5m / Total Stockholder Equity 1.34b)
RoCE = -9.62% (EBIT -238.0m / Capital Employed (Equity 1.34b + L.T.Debt 1.14b))
RoIC = -8.90% (negative operating profit) (NOPAT -220.7m / Invested Capital 2.48b)
WACC = 5.01% (E(1.85b)/V(3.11b) * Re(7.94%) + D(1.26b)/V(3.11b) * Rd(0.77%) * (1-Tc(0.07)))
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -2.57%
Fair Price DCF = unknown (Cash Flow -343.6m)
EPS Correlation: 44.98 | EPS CAGR: 8.07% | SUE: 0.46 | # QB: 0
Revenue Correlation: 82.36 | Revenue CAGR: 17.15% | SUE: 1.85 | # QB: 5

Additional Sources for SRPT Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle